Indian Competition Act and Insurance: Merger Control Filings for Insurer M&A and Broker Consolidation

The Competition Commission of India (CCI) regulates combinations (mergers, acquisitions, and amalgamations) under Sections 5 and 6 of the Competition Act, 2002. Any combination meeting the asset or turnover thresholds in Section 5 requires mandatory pre-closing notification to the CCI, and the transaction cannot be consummated until CCI approval (or deemed approval after the statutory waiting period) is received. The Competition Act applies to the insurance sector with the same force as any other industry, and CCI approval runs in parallel to the sector-specific approval required from IRDAI under the Insurance Act, 1938.

Insurance M&A in India has entered an active phase. The IRDAI composite licence framework, operationalised through the 2025 amendments to the insurance regulatory regime, allows a single insurer to underwrite both life and non-life business. This has prompted strategic reviews across large Indian financial conglomerates and opened new paths for foreign reinsurer entry. Broker consolidation has accelerated as global broking houses seek scale in the Indian market and smaller domestic brokers face rising compliance and technology costs. TPA consolidation and insurtech acquisitions have added a further layer of deal activity.

For any of these transactions, the first question is not strategic fit but whether CCI filing is required. A deal that exceeds the thresholds but escapes the de minimis exemption is a notifiable combination, and proceeding without notification or consummating before approval exposes the parties to penalties of up to 1 per cent of the total turnover or assets of the combination under Section 43A. The CCI has imposed gun-jumping penalties in the insurance sector before, and the amounts have been material.

Deal teams should therefore run the CCI analysis in parallel with the IRDAI analysis from the earliest stage of transaction planning. The two regulators address different concerns (CCI focuses on competition in relevant markets, IRDAI focuses on policyholder protection and insurer solvency), and both approvals must be coordinated to ensure the deal closes on schedule.

Section 5 of the Competition Act prescribes two sets of thresholds: a parties test (focused on the acquirer and target) and a group test (focused on the wider corporate group post-acquisition). Both tests operate on an either-or basis across asset value and turnover, and the jurisdictional thresholds have been indexed from their original 2002 levels to reflect inflation.

Under the current thresholds as indexed through notifications issued by the Ministry of Corporate Affairs, the parties test is met if the combined Indian assets of the acquirer and target exceed INR 2,000 crore, or if the combined Indian turnover exceeds INR 6,000 crore. The global test adds an overseas dimension: worldwide assets of USD 1 billion with at least INR 1,000 crore in Indian assets, or worldwide turnover of USD 3 billion with at least INR 3,000 crore in Indian turnover.

The group test applies to the enlarged group post-acquisition. A combination is notifiable if the acquiring group has Indian assets exceeding INR 8,000 crore, or Indian turnover exceeding INR 24,000 crore. The global group thresholds are USD 4 billion in worldwide assets with INR 1,000 crore Indian nexus, or USD 12 billion in worldwide turnover with INR 3,000 crore Indian nexus.

For an Indian insurer acquisition, the asset base of a regulated insurer makes the thresholds relatively easy to cross. A mid-sized non-life insurer with gross written premium of INR 15,000 crore and investment assets of INR 30,000 crore on its balance sheet will comfortably exceed the parties test on both metrics. For a composite licence merger combining a life and non-life insurer, the combined balance sheet will almost always trigger the group test. Deal teams should not assume sub-threshold status without a rigorous calculation; the book value of investment portfolios, reinsurance recoverables, and deferred acquisition costs can push insurers over the thresholds unexpectedly.

For brokers and insurtechs, the thresholds are less easily met. A domestic broker with annual commission revenue of INR 200 crore and assets of INR 150 crore is unlikely to trigger CCI filing unless combined with a large global acquirer whose Indian presence elevates the group numbers. The analysis must be done for each deal, not assumed from industry typicals.

The de minimis exemption, introduced through Ministry of Corporate Affairs notifications and now reflected in the Competition (Criteria for Exemption of Combinations) Rules, exempts transactions where the target enterprise has Indian assets below INR 450 crore and Indian turnover below INR 1,250 crore. The exemption is a target-only test: the acquirer's size is irrelevant, only the target's footprint in India matters.

For insurtech acquisitions, the de minimis exemption is often decisive. Many Indian insurtech startups, even well-funded ones, have balance sheets well below INR 450 crore and revenues below INR 1,250 crore. A global insurer acquiring an Indian insurtech with INR 80 crore in assets and INR 150 crore in revenue will generally not require CCI filing, because the target falls within the de minimis exemption, even though the combined entity is vastly larger than the thresholds.

The exemption applies at the entity level, not the deal level. If the transaction involves the acquisition of a business undertaking rather than a whole enterprise, the assets and turnover attributable to the acquired undertaking are assessed, not the seller's total assets. This can create acquisition structuring opportunities where a large insurer carves out a specific business line for sale and the carve-out's standalone numbers fall below the de minimis threshold.

However, the exemption is not available where there are multiple transactions between the same parties that are connected in time and substance. The CCI has scrutinised deals structured as a series of small acquisitions and has occasionally disregarded the de minimis exemption when the underlying economic reality involves a larger combined transaction. The safer course, in borderline cases, is to seek informal guidance from the CCI's Combinations Division before proceeding.

For TPA acquisitions, the exemption typically applies because even large Indian TPAs rarely exceed INR 450 crore in assets. For broker acquisitions below the mid-market, the exemption also generally applies. For any acquisition where IRDAI approval is required, parties should ensure that the CCI exemption position is documented in the deal file even if no CCI filing is made, so that the exemption can be defended if later challenged.

The 2025 composite licence reforms have opened strategic deal pathways that did not previously exist. Under the pre-2025 regime, life and non-life insurance had to be conducted in separate legal entities, preventing composite structures. The composite licence reform allows a single insurer to underwrite life, general, and health business under one regulatory umbrella, subject to capital and governance requirements.

Two deal archetypes have emerged from this reform. The first is the intra-group composite merger, where a financial conglomerate combines its life and non-life subsidiaries into a single composite insurer. Deals of this type (for example, HDFC Life and HDFC Ergo hypothetical combinations or the realised SBI Life and SBI General type structures) generally cross CCI thresholds easily given the combined balance sheets involved.

The second archetype is the foreign reinsurer entry deal. The FDI cap for insurance has been progressively raised to 100 per cent for specified categories of insurance businesses, and foreign reinsurers entering India through acquisition or joint venture structures now have viable paths to majority or full ownership. Deals involving Munich Re, Swiss Re, SCOR, and Lloyd's syndicate managing agencies acquiring stakes in Indian insurers or setting up branches typically trigger CCI filing because the combined Indian assets post-deal exceed the thresholds when the acquirer's Indian subsidiary and the target are aggregated.

CCI assessment for these transactions focuses on market share in the relevant product and geographic markets. The relevant market for non-life insurance is generally defined at the line-of-business level (motor, fire, marine, health, D&O, cyber), and market shares are measured by gross written premium. A transaction taking the combined market share above 15 per cent in any line of business is likely to attract substantive scrutiny. The CCI will also examine unilateral effects (the combined entity's incentive to raise prices), coordinated effects (whether the deal makes coordination among remaining insurers more likely), and barriers to entry.

IRDAI's parallel approval under the Insurance Act and the IRDAI (Registration of Indian Insurance Companies) Regulations focuses on different criteria: fit and proper acquirer, source of funds, solvency post-transaction, and policyholder protection. The two approvals interact but do not substitute for one another, and both must be secured before closing.

Broker consolidation in India has accelerated since the 2025 composite licence framework was extended to brokers, allowing a single broking entity to distribute life, general, health, and reinsurance products without maintaining separate licences. The administrative simplification has unlocked deals that were previously complicated by the need to hold multiple broking licences across group companies.

Foreign broker acquisitions of Indian broking entities are a principal driver of the consolidation wave. Marsh, Aon, WTW, Howden, Gallagher, and Lockton have all either entered India directly or expanded through acquisition of domestic brokers. Deals of this type involve Competition Act analysis at three layers: the parties test (usually crossed given the acquirer's Indian group footprint), the group test (almost always crossed for global broker acquirers), and the de minimis exemption (rarely available given the strategic nature of the target).

The relevant market analysis for broker M&A is subtle. The CCI has historically treated insurance broking as a single market, but broker specialisation has increased to the point where reinsurance broking, large commercial broking, SME broking, and retail broking may each be assessed as distinct markets. Market share is measured by brokerage revenue, premium placed, or a combination of the two. For deals involving specialised reinsurance brokers, the market shares can be high enough to trigger substantive review even when the total broking market share is modest.

The CCI has also considered vertical integration concerns where a broker acquisition connects to insurer ownership. If a broker group is controlled by the same parent as an insurer, the CCI examines whether the broker can be used to steer business preferentially to the affiliated insurer, distorting the client's duty of disclosure and the broker's fiduciary role. IRDAI's parallel review of broker fit and proper status and its separate scrutiny of conflicts of interest add another dimension.

For domestic broker consolidation deals below the de minimis threshold, no CCI filing is required but parties should still document the analysis. For cross-border deals involving foreign acquirers, CCI filing is almost always required, and the Phase I review typically takes 30 working days from acceptance of a complete notification.

Third-party administrators and insurtech platforms have been the most active segments in Indian insurance M&A by deal count, if not by deal value. TPA consolidation is driven by scale economics in claims processing and network hospital management, while insurtech M&A reflects the convergence of technology and distribution in a rapidly digitising market.

For TPA acquisitions, CCI analysis focuses on two relevant markets: TPA services to insurers (the wholesale market where insurers contract TPAs for claims administration) and hospital network access (where TPAs negotiate rates with hospitals). Market concentration in TPA services is already moderate to high, with the top five TPAs handling a majority of health claims volume. Further consolidation in this market attracts scrutiny, particularly where the deal would reduce the number of independent TPAs available to insurers below a competitive threshold.

The de minimis exemption is generally available for TPA deals where the target's Indian assets are below INR 450 crore, which covers most standalone TPAs. Where the deal involves a TPA embedded within a larger healthcare or insurance group, the exemption may not apply, and the parent's aggregate numbers must be used.

Insurtech acquisitions span a wide range: distribution platforms, claims automation tools, underwriting data providers, telematics platforms, and health-tech integrations. The CCI's approach to insurtech deals has been generally permissive, recognising that most insurtech targets are below de minimis thresholds and that the acquirer typically brings regulatory and capital strength that the target lacks. However, the CCI has flagged potential concerns in deals where an acquirer builds a portfolio of insurtech assets that together could influence market structure, and has occasionally looked beyond individual transactions to the cumulative effect of a series of acquisitions.

For deal teams, the practical advice is to run the threshold calculation on every insurtech transaction, even where the target appears obviously small. Convertible notes, employee stock option pools, and warrants can inflate the effective transaction size, and the CCI looks at transaction value as well as target balance sheet when assessing notifiability in borderline cases.

CCI merger review operates on a green channel and a standard track. The green channel, introduced in 2019, allows qualifying combinations to be deemed approved immediately upon filing, provided the parties have no horizontal or vertical overlaps and no group company operates in the relevant market. Insurance deals rarely qualify for green channel because the acquirer and target typically operate in overlapping lines of business, but green channel should always be checked before assuming a standard filing is required.

The standard track involves Phase I review, which has a statutory 30 working day timeline from the date of acceptance of a complete notification. Most insurance deals clear in Phase I, particularly where market shares are modest and no plausible anti-competitive effect arises. The CCI may approve unconditionally, approve subject to voluntary modifications (behavioural or structural undertakings given by the parties), or refer the deal to Phase II.

Phase II review is triggered when the CCI forms a prima facie opinion that the combination is likely to cause an appreciable adverse effect on competition. Phase II has a statutory outer limit of 210 calendar days, though in practice clearance can take longer when information requests extend the review. During Phase II, the CCI typically issues detailed information requests, holds consultations with market participants (competitors, customers, trade associations), and considers remedies ranging from structural divestitures to behavioural undertakings.

Green flag indicators for insurance deals include combined market share below 15 per cent in each affected line of business, multiple remaining competitors with credible offerings, no vertical integration concerns between broker and insurer, and no coordinated effects risk. Red flag indicators include combined market share above 25 per cent, concentration in specialised lines such as aviation or energy where the insurer count is small, vertical integration creating foreclosure risk for competitors, and geographic concentration in underserved regions.

Precedent matters in managing CCI expectations. The HDFC Ergo and Apollo Munich health insurance merger, cleared in 2020, established the analytical template for health-focused insurer combinations. The Bharti AXA General Insurance acquisition by ICICI Lombard, cleared in 2021 with no conditions after Phase I, set expectations for non-life consolidation. Both deals were cleared without divestitures because the combined market shares remained within competitively safe ranges. Deal teams should study these precedents when preparing the competitive assessment memorandum for new filings.

The CCI and IRDAI approval processes run in parallel but involve different regulators, different statutory frameworks, and different review criteria. CCI focuses on competition: relevant market definition, market shares, competitive effects, and remedies. IRDAI focuses on prudential and policyholder considerations: acquirer fit and proper, source of funds, post-deal solvency, and continuity of service to policyholders. Both approvals are typically conditions precedent to closing under the share purchase agreement.

Timing alignment is the practical challenge. CCI Phase I approval is statutorily 30 working days but often takes longer when information requests extend the review. IRDAI approval timelines vary by deal type but typically run to 90 to 120 days for standard insurer acquisitions, longer for deals involving foreign acquirers or complex group restructuring. Deal teams should plan for the longer of the two approval processes to drive the closing date.

Conditional approvals add another dimension. CCI conditional approvals typically involve voluntary modifications such as divestiture of overlapping portfolios, behavioural undertakings on pricing, or limitations on information sharing between the merging parties post-closing. IRDAI conditional approvals may involve capital commitments, restrictions on dividend distribution for a specified period, or continuity obligations on existing policyholders. Both sets of conditions must be reflected in the closing mechanics and the post-closing integration plan.

Coordination between the CCI and IRDAI is generally ad hoc rather than institutionalised. The two regulators do not jointly review transactions, though they may exchange information informally. Parties filing with both regulators should ensure consistency in the facts presented, the market data relied upon, and the remedies offered. Discrepancies between the CCI filing and the IRDAI filing can trigger additional queries from either regulator and delay approval.

For foreign acquirers, a third regulatory thread runs in parallel: FDI approval under the Press Note route or automatic route depending on the insurance sub-sector and acquirer nationality. The Foreign Investment Facilitation Portal (FIFP) processes sensitive sector approvals, and the timeline can extend the overall deal calendar further. Well-advised deal teams map all three regulatory approvals (CCI, IRDAI, FIFP where applicable) at signing and build cushion into the long stop date in the SPA to account for regulatory delay.